Abstract:To explain the low bioavailability of sibiricaxanthone F (SF) following oral administration and to predict its possible metabolites in vivo, the in vitro biotransformation of SF and its metabolic stability in intestinal bacteria (BI) were studied. The metabolism of SF and its aglycone (1,3,6-trihydroxy-2,7-dimethoxyxanthone, Xan) was characterized after incubation with human and rat liver microsomes (HLMs and RLMs). The chemical structures of the metabolites were tentatively identified on the basis of their mass profiles using high performance liquid chromatography coupled with an enhanced mass spectrometry-information dependent acquisition-enhanced product ion (EMS-IDA-EPI) scan mode on a hybrid triple quadrupole-linear ion trap mass spectrometer. The metabolic stability of SF in BI was determined using the multiple reaction monitoring (MRM) mode. As a result, five hydrolyzed metabolites (M1–M4 and Xan) were generated stepwise for SF when it was incubated with BI, whereas two demethylated products (M1 and M5) were detected for Xan in BI. The metabolic stability study of SF in BI revealed that the parent compound could be rapidly hydrolyzed by BI and that Xan, the main corresponding metabolite, increased rapidly. In RLMs and HLMs, two hydrolyzed metabolites (M2 and M3) mediated by CYP450 isoenzymes appeared for SF in the presence of an NADPH-regenerating system, whereas no metabolite was detected for Xan under the same conditions. One (M6) and three glucuronidated metabolites (M7–M9) were generated from SF and Xan, respectively, by phase II isoenzymes in liver microsomal proteins in the presence of uridine 5′-diphosphoglucuronic acid (UDPGA). Overall, the present study revealed that extensive first-pass elimination occurred for SF in intestinal bacteria and hepatic subcellular proteins in vitro, which could be one of the main reasons for the low bioavailability of SF; furthermore, the possible SF-related metabolites in rats and humans were elucidated to be mono-glucuronidated derivatives of Xan following oral administration of SF.

[Biotransformation of mogroside III by human intestinal bacteria].

Stability of mogroside V in artificial gastric juice and its metabolism in vitro

Metabolism of Two Mogroside Isomers, Mogroside III and Mogroside IIIE, in Normal and Drug-Metabolizing Enzyme-Induced Rats.

NMR Structural Elucidation of Mogrol and Its Glycosides

[The Biotransformation of Kaempferitrin by Human Intestinal Flora].

Assignments of 1H and 13C NMR Signals of Mogroside IVa

Biotransformation of Three Free Anthraquinones by Mucor Spinosus

Microbial transformation of deoxyandrographolide by Fusarium graminearum AS 3.4598

Rationally Engineered Novel Glycosyltransferase UGT74DD1 from Siraitia grosvenorii Catalyzes the Generation of the Sweetener Mogroside III

Methodology of enzymic hydrolysis of fifty percent mogroside V

Mulberry anthocyanin biotransformation by intestinal probiotics

The Biotransformation of Bupleuri Radix by Human Gut Microbiota

Microbial Glycosylation of Cardamonin by Mucor Spinosus.

Biotransformation and metabolism of three methyl salicylate glycosides by gut microbiota in vitro

Three New Isoflavonoid Glycosides From The Mangrove-Derived Actinomycete Micromonospora Aurantiaca 110b

In vitro human intestinal microbiota biotransformation of nobiletin using liquid chromatography–mass spectrometry analysis and background subtraction strategy

Grosmomoside I , a new cucurbitane triterpenoid glycoside from fruits of Momordica grosvenori

Characterization of the metabolism of sibiricaxanthone F and its aglycone in vitro by high performance liquid chromatography coupled with Q-trap mass spectrometry.

Microbiological Transformation of Ginsenoside Rg1

Biotransformation of two citrus flavanones by lactic acid bacteria in chemical defined medium

Identification of a Novel Ibuprofen Biotransformation Pathway in Streptomyces sp. D218 and Detoxification as Indicated by the Green Algae Scenedesmus obliquus